A Step Forward in c-Met-Targeted Therapy in NSCLC
Nicolas Girard, MD, PhD, discusses patient-reported outcomes from the LUMINOSITY trial of telisotuzumab vedotin in NSCLC.
Telisotuzumab vedotin (Teliso-V), a c-Met-directed antibody-drug conjugate, demonstrated promising results in the phase 2 LUMINOSITY trial (NCT03539536) in patients with non–small cell lung cancer (NSCLC).
The drug showed efficacy in patients with c-Met overexpression and manageable safety and had a manageable safety profile. Patients reported improvements in cough, chest pain, and overall quality of life. Deterioration in peripheral neuropathy was observed, but it was manageable. Patients with disease control experienced delayed deterioration in quality of life, dyspnea, and physical functioning. Responders to Teliso-V had delayed deterioration in quality of life compared to nonresponders.
The phase 3 TeliMET NSCLC-01 trial (NCT04928846) will further assess the impact of Teliso-V on quality of life to confirm the trends observed in the LUMINOSITY trial.
Here, Nicolas Girard, MD, PhD, thoracic oncologist at the Institut Curie in Paris, France, discusses the outcomes from LUMINOSITY.
Transcription:
0:05 | What we see from the LUMINOSITY trial is that we have an improvement in the key symptoms of dyspnea and cough and chest pain, which are actually actually improved as reported by the patient, and this is related to the high response rates that we see with Teliso-V. We also see a deterioration in peripheral neuropathy, as expected, because this is one of the most frequent side effects, mostly grade 1/2, and in 10% of patients grade 3 or higher. So we are reflecting the efficacy and the safety. In this analysis of patient-reported outcomes, what we see is that the other parameters, other symptoms, quality of life and physical functioning, are maintained along with the treatment with Teliso-V who are able also to look at time to deterioration in quality of life, which is again a way to have an insight into the balance between efficacy and safety. And actually it was more prolonged time to deterioration of quality of life. It was more prolonged not only in responders, but also in patients with stable disease.
